SUPPLEMENTARY FIGURES

OS Study or Subgroup	log [Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95%CI	Hazard Ratio IV, Fixed, 95%CI
Rosenberg 2002	0.1484	0.196	3.6%	1.16 [0.79, 1.70]	
Katsumata 2013	-0.2357	0.1155	10.3%	0.79 [0.63, 0.99]	-
Pignata 2014	0.174	0.1313	8.0%	1.19 [0.92, 1.54]	.
Chan 2016	-0.0619	0.136	7.5%	0.94 [0.72, 1.23]	4
Perez 2005	0.6539	0.955	0.2%	0.52 [0.08, 3.38]	
Seidman 2008	-0.2485	0.093	15.9%	0.78 [0.65, 0.94]	•
Sparano 2008	0.2776	0.1315	8.0%	1.32 [1.02, 1.71]	-
Schuette 2006	0.0296	0.0745	24.9%	1.03 [0.89, 1.19]	L
Socinski 2006	-0.2744	0.1839	4.1%	0.76 [0.53, 1.09]	
Belani 2007	-0.2357	0.2542	2.1%	0.79 [0.48, 1.30]	
Belani 2008	0.0862	0.1092	11.6%	1.09 [0.88, 1.35]	· · · · · · · · · · · · · · · · · · ·
Socinski 2009	0.2231	0.2277	2.7%	1.25 [0.80, 1.95]	
Sakakibara 2010	0.207	0.3333	1.2%	1.23 [0.64, 2.36]	
Total (95% CI)			100%	0.98 [0.91, 1.06]	
Heterogeneity: Chi^2	= 23.73, df $= 12$ (P $= 0.02$		$\vdash $		
Test for overall effect:	, , ,	0.01 0.1 1 10 100			
					Favours [Weekly] Favours [3-weeks]

Supplementary Figure 1. The forest plot of HR for OS in the weekly paclitaxel compared to 3-weeks paclitaxel regimen. HR: hazard ratio; OS: overall survival.

OS				Hazard Ratio	Hazard Ratio
Study or Subgroup	log [Hazard Ratio]	SE	Weight	IV, Random, 95%C	I IV, Random, 95%CI
1. Overall survival in	the weekly dose-dense	analysis			
Pignata 2014	0.174	0.1313	14.3%	1.19 [0.92, 1.54]	+ - -
Schuette 2006	0.0296	0.0745	25.6%	1.03 [0.89, 1.19]	+
Subtotal (95% CI)			39.9%	1.07 [0.94, 1.21]	•
Heterogeneity: Chi^2 Test for overall effect:	= 0.91, df = 1 (P = 0.34); Z = 1.00 (P = 0.32)	I^2 = 0%			
2. Overall survival in	the semi-weekly dose-d	ense analy	sis		
Belani 2008	0.0862	0.1092	17.9%	1.09 [0.88, 1.35]	
Chan 2016	-0.0619	0.136	13.6%	0.94 [0.72, 1.23]	_ _
Katsumata 2013	-0.2357	0.1155	16.7%	0.79 [0.63, 0.99]	
Sakakibara 2010	0.207	0.3333	3.1%	1.23 [0.64, 2.36]	
Socinski 2006	-0.2744	0.1839	8.7%	0.76 [0.53, 1.09]	
Subtotal (95% CI)			60.1%	0.92 [0.78, 1.08]	•
Heterogeneity: Chi^2 Test for overall effect:	= 6.10, df = 4 (P = 0.20); Z = 1.02 (P = 0.31)	I^2 = 33%			
Total (95% CI)			100%	0.98 [0.87, 1.11]	
Test for overall effect:	= 9.48, df = 6 (P = 0.15); Z = 0.29 (P = 0.77) erences: Chi 2 = 2.02, df	0.1 0.2 0.5 1 2 5 10 Favours [Weekly] Favours [3-weeks]			


Supplementary Figure 2. The forest plot of HR for OS in the subgroup analysis based on carboplatin administration schedules. HR: hazard ratio; OS: overall survival.

OS				Hazard Ratio	Hazard Ratio
Study or Subgroup	log [Hazard Ratio]	SE	Weight	IV, Random, 95%	CI IV, Random, 95%CI
1. Overall survival in	the DDR > 1 group				
Katsumata 2013	-0.2357	0.1155	10.6%	0.79 [0.63, 0.99]	-
Chan 2016	-0.0619	0.136	9.1%	0.94 [0.72, 1.23]	+
Seidman 2008	-0.2485	0.093	12.4%	0.78 [0.65, 0.94]	-
Sparano 2008	0.2776	0.1315	9.4%	1.32 [1.02, 1.71]	<u>_</u>
Tubtotal (95% CI)			41.4%	0.93 [0.73, 1.17]	•
Heterogeneity: Chi^2 = Test for overall effect:	= 12.21, df = 3 (P = 0.007 Z = 0.65 (P = 0.51)	7); I^2 = 759	vo		
2. Overall survival in	the DDR < = 1 group				
Rosenberg 2002	0.1484	0.196	5.9%	1.16 [0.79, 1.70]	
Pignata 2014	0.174	0.1313	9.4%	1.19 [0.92 1.54]	-
Perez 2005 Schuette 2006	-0.6539 0.0296	0.955 0.0745	0.4% 14.0%	0.52 [0.08, 3.38] 1.03 [0.89, 1.19]	
Socinski 2006	-0.2744	0.1839	6.4%	0.76 [0.53, 1.09]	
Belani 2007	-0.2357	0.2542	4.1%	0.79 [0.48, 1.30]	
Belani 2008	0.0862	0.1092	11.0%	1.09 [0.88, 1.35]	+-
Socinski 2009	0.2231	0.2277	4.8%	1.25 [0.80, 1.95]	
Sakakibara 2010	0.207	0.3333	2.6%	1.23 [0.64, 2.36]	-
Subtotal (95% CI)			58.6%	1.05 [0.95, 1.15]	+
Heterogeneity: Chi^2 = Test for overall effect:	= 7.04, df = 8 (P = 0.53); Z = 0.98 (P = 0.33)	I^2 = 0%			
Total (95% CI)			100.0%	0.99 [0.88, 1.11]	•
Test for overall effect:	= 23.73, df = 12 (P = 0.02 Z = 0.17 (P = 0.87) prences: Chi ² = 0.95 , df	Image: Constraint of the second sec			


Supplementary Figure 3. The forest plot of HR for OS in the subgroup analysis based on the DDR of paclitaxel. HR: hazard ratio; OS: overall survival; DDR: dose density ratio.

OS				Hazard Ratio	Hazard Ratio				
Study or Subgroup	log [Hazard Ratio]	SE	Weight	IV, Random, 95%CI	IV, Random, 95%CI				
1. Overall survival in North American									
Chan 2016	-0.0619	0.136	9.1%	0.94 [0.72, 1.23]	-				
Perez 2005	0.6539	0.955	0.4%	0.52 [0.08, 3.38]					
Seidman 2008	-0.2485	0.093	12.4%	0.78 [0.65, 0.94]	-				
Sparano 2008	0.2776	0.1315	9.4%	1.32 [1.02, 1.71]	-				
Socinski 2006	-0.2744	0.1839	6.4%	0.76 [0.53, 1.09]					
Belani 2007	-0.2357	0.2542	4.1%	0.79 [0.48, 1.30]					
Belani 2008	0.0862	0.1092	11.0%	1.09 [0.88, 1.35]	<u> </u>				
Socinski 2009	0.2231	0.2277	4.8%	1.25 [0.80, 1.95]	\mathbf{T}^{-}				
Subtotal (95% CI)			57.6%	0.97 [0.81, 1.15]	Ť				
Heterogeneity: Tau ² = Test for overall effect:	= 0.03, Chi 2 = 16.18, df Z = 0.40 (P = 0.69)	f = 7 (P = 0.0)	02); I^2 = 57	%					
2. Overall survival in	Europe								
Rosenberg 2002	0.1484	0.196	5.9%	1.16 [0.79, 1.70]					
Pignata 2014	0.174	0.1313	9.4%	1.19 [0.92 1.54]	+				
Schuette 2006	0.0296	0.0745	14.0%	1.03 [0.89, 1.19]	t				
Subtotal (95% CI)			29.3%	1.08 [0.95, 1.21]	•				
Heterogeneity: Tau ² = Test for overall effect:	= 0.00, $Chi^2 = 1.08$, df = Z = 1.19 (P = 0.24)	= 2 (P = 0.58)	3); I^2 = 0%						
3. Overall survival in	Asia								
Katsumata 2013	-0.2357	0.1155	10.6%	0.79 [0.63, 0.99]	-				
Sakakibara 2010	0.207	0.3333	2.6%	1.23 [0.64, 2.36]					
Subtotal (95% CI)			13.2%	0.88 [0.61, 1.29]	•				
Heterogeneity: Tau ² = Test for overall effect:	= 0.04, Chi 2 = 1.58, df = Z = 0.65 (P = 0.52)	= 1 (P = 0.2)	l); I^2 = 37%	, 0					
Total (95% CI)			100.0%	0.99 [0.88, 1.11]	•				
Heterogeneity: Tau^2 = 0.02, Chi^2 = 23.73, df = 12 (P = 0.02); I^2 = 49% Test for overall effect: Z = 0.17 (P = 0.87) Test for subgroup differences: Chi^2 = 1.68, df = 2 (P = 0.43), I^2 = 0% Favours [Weekly] Favours [3-weeks]									

Supplementary Figure 4. The forest plot of HR for OS in the subgroup analysis based on ethnic differences of included populations. HR: hazard ratio; OS: overall survival.



Supplementary Figure 5. The forest plot of OR for non-hematologic toxicities (vomiting, nausea, infection, fatigue, dyspnea, diarrhea, constipation, arthritis, alopecia, and neuropathy) in the weekly paclitaxel compared to 3-weeks paclitaxel regimen. OR: odds ratio.



Supplementary Figure 6. The funnel plots for publication bias. (A) for articles measuring the incidence of OS. (B) for articles measuring the incidence of PFS. (C) for articles measuring the incidence of ORR. The vertical blue dotted line and two oblique blue dotted lines represent the position of the combined effect value and its corresponding 95% confidence interval on the x-axis, respectively. The red arrows point to outlier studies. OS: overall survival; PFS: progression-free survival; ORR: overall response rate.

PFS Study or Subgroup	log [Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95%CI	Hazard Ratio IV, Fixed, 95%CI
Rosenberg 2002	0.0488	0.1717	2.4%	1.05 [0.75, 1.47]	+
Katsumata 2013	-0.2744	0.1039	6.6%	0.76 [0.62, 0.93]	-
Pignata 2014	-0.0408	0.093	8.2%	0.96 [0.80, 1.15]	+
Chan 2016	-0.1165	0.0942	8.0%	0.89 [0.74, 1.07]	-
Clamp 2019	-0.0943	0.0594	20.2%	0.91[0.81, 1.02]	-
Perez 2005	-0.4463	0.4403	0.4%	0.64 [0.27,1.52]	
Seidman 2008	-0.3011	0.0821	10.6%	0.74 [0.63, 0.87]	+
Schuette 2006	0.1398	0.0713	14.0%	1.15[1.00, 1.32]	-
Belani 2007	-0.3425	0.2105	1.6%	0.71 [0.47, 1.07]	
Belani 2008	-0.0408	0.093	8.2%	0.96 [0.80, 1.15]	+
Socinski 2009	-0.1054	0.143	3.5%	0.90 [0.68, 1.19]	+
Sakakibara 2010	-0.1744	0.1978	1.8%	0.84 [0.57, 1.24]	
Blank 1	0.327	0.4403	0.4%	1.39 [0.59, 3.29]	
Blank 2	0.0005	0.0713	14.0%	1.00 [0.87, 1.15]	+
Total (95% CI)			100%	0.93 [0.88, 0.98]	•
Heterogeneity: Chi^2 = Test for overall effect:	= 26.01, df = 13 (P = 0.02 Z = 2.89 (P = 0.004)	2); I^2 = 50%	b	0.01	0.1 1 10 100 Favours [Weekly] Favours [3-weeks]

Supplementary Figure 7. The forest plot of adjusted HR by trim and fill for PFS in the weekly paclitaxel compared to 3-weeks paclitaxel regimen. HR: hazard ratio; PFS: progression-free survival.

Errata	Wee	kly 3-weeks		Odds Ratio			Odds Ratio			
Study or Subgroup	Events Total Events Total		Weight	M-H, Fixed, 95%CI M-H, Fixed, 95%CI		, 95%CI				
Schuette 2006	165 434 148 449		54.8%	1.25 [0.95, 1.64]						
Socinski 2009	19 84 23 81		11.0%	0.74 [0.36, 1.49]		_ _				
Socinski 2006	28 79 26 80		10.1%	1.14 [0.59, 2.20]						
Belani 2008	60 217 41 214		18.1%	1.61 [1.03, 2.53]		_				
Sakakibara 2010	23	42	21	40	5.9%	1.10[0.46, 2.61]			_	
Total (95% CI)		856		864	100.0%	1.24 [1.01, 1.52]		♦		
Total events	295		259							
Heterogeneity: Chi 2 = 3.54, df = 4 (P = 0.47); I 2 = 0%										
Test for overall effect: Z	= 2.04 (P	= 0.04)					0.01	0.1 1	10	100
								Favours [Weekly]	Favours [3-w	/eeks]

Supplementary Figure 8. The corrected forest plot of OR for response rate in the weekly paclitaxel compared to 3-weeks paclitaxel regimen.